Polymyxin B Sulfate

CHEMBL5314355 Phase 4 Одобрено Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

Polymyxin B sulfate is the sulfate salt form of polymyxin B, a last-resort cyclic lipopeptide antibiotic targeting the outer membrane of Gram-negative bacteria including multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. See polymyxin b for complete pharmacological details.

Терапевтические области

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

Polymyxin B sulfate is the sulfate salt form of polymyxin B, a last-resort cyclic lipopeptide antibiotic targeting the outer membrane of Gram-negative bacteria including multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. See polymyxin b for complete pharmacological details.

Yes, Polymyxin B Sulfate is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5314355. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.